Direct thrombin inhibitors for the treatment of acute coronary syndromes and during percutaneous coronary interventions

Current Pharmaceutical Design

Volumn 11, Issue 30, 2005, Pages 3919-3929

  Paoli, Giorgia ^a   Merlini, P A ^b   Ardissino, D ^b  

^a MAGGIORE HOSPITAL   (Italy)

^b NONE

Author keywords

Acute coronary syndrome; Direct thrombin inhibitors; Heparin; Percutaneous coronary intervention

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ARGATROBAN; CLOPIDOGREL; EFEGATRAN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRUDIN; HIRULOG; INOGATRAN; LEPIRUDIN; PLACEBO; STREPTOKINASE; THROMBIN; THROMBIN INHIBITOR; TICLOPIDINE; TISSUE PLASMINOGEN ACTIVATOR;

BLEEDING; BOLUS INJECTION; BRAIN HEMORRHAGE; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG FATALITY; FIBRINOLYSIS; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; ST SEGMENT ELEVATION; THROMBOSIS; UNSTABLE ANGINA PECTORIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; CORONARY ARTERIOSCLEROSIS; ELECTROCARDIOGRAPHY; FIBRINOLYTIC AGENTS; HUMANS; INTRAOPERATIVE COMPLICATIONS; MYOCARDIAL INFARCTION; THROMBIN;

EID: 27744501178     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161205774580606     Document Type: Review

References (44)

1. Collaborative overview of randomized trials of antiplatellet therapy. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994; 308: 81-106.
2. Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndromes without ST elevation: a meta-analysis. Lancet 2000; 355: 1936-1942.
3. Lefkovits J, Topol E. Direct thrombin inhibitors in cardiovascular medicine. Circulation 1994; 90:1522-1536.
4. Weitz JI, Buller HR. Direct Thrombin Inhibitors in Acute Coronary Syndromes Present and Future. Circulation 2002; 105: 1004-1011.
5. Weitz JI, Hirsh J. New Anticoagulant Drugs. Chest 2001; 119: 95s-107s.
6. Fuchs J, Cannon CP, and the TIMI 7 Investigators Hirulog in the Treatment of Unstable Angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 Trial. Circulation 1995; 92: 727-733.
7. Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators Comparison of the Effects of Two Doses of Recombinant Hirudin Compared With Heparin in Patients With Acute Myocardial Ischemia Without ST Elevation A Pilot Study, Circulation 1997; 96: 769-777.
8. TRIM Study Group. A low molecular weight, specific thrombin inhibitor, inogatran, versus heparin, in unstable coronary artery disease in 1209 patients: a double blind, randomized dose finding study. Eur Heart J 1997; 18: 1416-1425.
9. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994; 90: 1631-7
10. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996; 335: 775-82.
11. Effects of recombinant hirudin (lepirudin) compared with heparin death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomized trial. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Lancet 1999; 353: 429-438.
12. Antman EM, McCabe CH, Braunwald E. for the TIMI 8 Investigators. Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: Observations from the TIMI 8 trial. Am Heart J 2002; 143: 229-34.
13. Klootwijk P, Lenderink T, Meij S, Boersma H, Melkert R, Umans VA, et al. Anticoagulant properties, clinical efficacy and safety of efegatran, a direct thrombin inhibitor, in patients with unstable angina. Eur Heart J 1999; 20: 1101 -1111.
14. Ohman EM, Califf RM, Topol EJ, Candela R, Abbottsmith C, Ellis S. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group Circulation 1990; 82: 781-791.
15. Cairns JA, Lewis HD Jr, Meade TW, Sutton GC, Theroux P. Anti-thrombotic agents in coronary artery disease. Circulation 1995; 95: 38OS-400S.
16. Cannon CP, McCabe CH, Henry TD, Schweiger MJ, Gibson RS, Mueller HS, el al. for the TIMI 5 Investigators. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 Trial. J Am Coll Cardiol 1994; 23: 993-1003.
17. Lee LV, for the TIMI 6 Investigators, Initial experience with hirudin and streptokinase in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction,(TIMI) 6 trial. Am J Cardiol 1995; 75: 7-13.
18. White HD, Aylward PE, Frey MJ, Adgey AA, Nair R, Hillis WS, et al. Randomized, double blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators. Circulation 1997; 96: 2155-61.
19. Jang IK, Brown DF, Giugliano RP, Anderson HV, Losordo D, Nicolau JC, et al. A multicentre, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA. (MINT) study. J Am Coll Cardiol 1999; 33: 1879-85.
20. Antman EM, for the TIMI 9A Investigators. Hirudin in acute myocardial infarction: safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial. Circulation 1994; 90: 1624-1630.
21. Antman EM and TIMI 9B Investigators. Hirudin in acute myocardial infarction. Thrombolysis and thrombin, inhibition in myocardial infarction (TIMI) 9B trial. Circulation 1996; 94: 911-21.
22. Metz BK, White HD, Granger CB, Simes RJ, Armstrong PW, Hirsh J, et al. Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for, acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators. J Coll Cardiol 1998; 31(7): 1493-8.
23. Neuhaus KL, Molhoek GP, Zeymer U, Tebbe U, Wegscheider K, Schroder, R. et al. for the HIT-4 Investigators. Recombinant hirudin (lepirudin) for the improvement of thrombolysis with strepto-kinase in patients with acute myocardial infarction. Results of the HIT-4 trial. J Am Coll Cardiol 1999; 34: 966-73.
24. White H, and the Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomized trial. Lancet 200 1; 358: 1855-63.
25. Wallentin L, Wilcox RG, Weaver WD, Emanuelsson H, Goodvin A, Nystrom P, et al. for the ESTEEM Investigators. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomized controlled trial. Lancet 2003; 362: 789-97.
26. Wolfe MW, Roubin GS, Schweiger M, Isner JM, Ferguson JJ, Cannon DA, et al. Length of hospital stay and complications after percutaneous transluminal coronary angioplasty: clinical and procedural predictors. Circulation 1995; 92: 311-9.
27. Serruys PW, Herrman J-PR, Simon F, Ritsch W, Bode C, Laarman G-J, et al. for the HELVETICA (Hirudin in a European Trial versus Heparin in the Prevention of Restenosis after PTCA) Investigators. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty N Engl J Med 1995; 333: 757-63.
28. Bittl JA, Strony J, Brinker JA, Ahmed WH, Meckel CR, Chaitman BR, et al. for the Hirulog Angioplasty Study Investigators. Treatment of bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or post-infarction angina. N Engl J Med 1995; 333: 764-9.
29. Bittl JA, Chaitman BR, Feit F, Kimball W, Topol EJ. for the Bivalirudin Angioplasty Study Investigators. Bivalirudin versus heparin during coronary angioplasty for unstable or post-infarction angina: Final report analysis of the Bivalirudin Angioplasty Study. Am Heart J 2001; 142: 952-9.
30. The EPIC Investigation. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-61.
31. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689-96.
32. The CAPTURE Investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997; 349: 1429-35.
33. The IMPACT-II Investigators. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet 1997; 349: 1422-8.
34. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction under-going coronary angioplasty. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. Circulation 1997; 96: 1445-53.
35. The EPISTENT Investigators. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998; 352: 87-92.
36. Brener SJ, Barr LA, Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 1998; 98: 734-41.
37. Lincoff AM, Kleiman NS, Kottke-Marchant K, Maierson ES, Maresh K, Wolski KE, et al. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J 2002; 143: 847-53.
38. REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial, JAMA 2003; 289: 853-63.
39. The Direct Thrombin Inhibitor Trialists' Collaborative Group. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis bazed on individual patients' data. Lancet 2002; 359: 294-302
40. Merlini PA, Ardissino D, Rosenberg RD, Colombi E, Agricola P, Oltrona L, et al. In vivo thrombin generation and activity during and after intravenous infusion of heparin or recombinant hirudin in patients with unstable angina pectoris. Arterioscler Thromb Vasc Biol 2000; 20(9): 2162-6.
41. Bahit MC, Topol EJ, Califf RM, Armstrong PW, Criger DA, Hasselblad V, et al, Reactivation of ischemic events in acute coronary syndromes: results from GUSTO-IIb. Gobal Use of Strategies To Open occluded arteries in acute coronary syndromes. Am Coll Cardiol 2001; 37(4): 1001-7.
42. Ahn HS, Chackalamannil S, Boykow G, Graziano MP, Forster C. Development of proteinase-activated receptor I antagonists as therapeutic agents for thrombosis, restenosis and inflammatory diseases. Curr Pharm Design 2003; 9(28): 2349-65.
43. Brener SJ, Topol EJ. Adjunctive therapy for percutaneous revascularization in acute myocardial infarction. Curr Pham Design 2004; 10(4):399-405.
44. Gould WR, Leadley RJ. Recent advances in the discovery and development of direct coagulation factor Xa inhibitors. Curr Pharm Design 2003; 9(28):2337-47.